{"id":"W2106185842","doi":"10.1212/wnl.0b013e3181e1cec2","title":"A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis","year":2010,"lang":"en","type":"article","venue":"Neurology","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":359,"is_retracted":false,"has_abstract":true,"ca_institutions":"Rockyview General Hospital; Hospital for Sick Children; McGill University; Etobicoke General Hospital; SickKids Foundation; University of Toronto; St. Michael's Hospital; Mount Sinai Hospital","funders":"Actelion Pharmaceuticals; National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Genentech; Multiple Sclerosis Society; National Institute of Diabetes and Digestive and Kidney Diseases; Multiple Sclerosis Society of Canada; EMD Serono; Elan; Immune Tolerance Network; Dairy Farmers of Canada; GlaxoSmithKline; Biogen; Sanofi; Teva Pharmaceutical Industries; Ono Pharmaceutical; Eli Lilly and Company","keywords":"Medicine; Tolerability; Vitamin D and neurology; Internal medicine; Expanded Disability Status Scale; Adverse effect; Clinical endpoint; Multiple sclerosis; Randomization; Vitamin; Clinical trial; Gastroenterology; Randomized controlled trial; vitamin D deficiency; Confounding; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002578298,0.00008507276,0.0002836647,0.0001831852,0.00004874096,0.000002576831,0.00004931781,0.0001344847,0.00002581462],"category_scores_gemma":[0.001169406,0.0000711957,0.00003427446,0.0001416471,0.0002732654,0.00003536072,0.0001090129,0.0004139579,0.000003524926],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000005000833,"about_ca_system_score_gemma":0.00003193041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000140863,"about_ca_topic_score_gemma":0.0003859521,"domain_scores_codex":[0.9991152,0.000081796,0.0002226449,0.0002164525,0.0001505149,0.000213377],"domain_scores_gemma":[0.9993352,0.000300787,0.00005134859,0.0001857001,0.00005488192,0.00007207428],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.03073547,0.001998837,0.0414543,0.00005041667,0.0000239378,0.0000466622,0.0004363721,9.475417e-7,0.9064826,0.00004293665,0.0003202322,0.0184073],"study_design_scores_gemma":[0.2104075,0.02294847,0.749238,0.0000142337,0.00003614687,0.00003159987,0.00001646619,0.001582834,0.01444738,0.00004985558,0.001138602,0.00008893061],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958444,0.00002131169,0.000008689526,0.003110018,0.0002612939,0.0005383947,0.000007053629,0.00001655316,0.0001922748],"genre_scores_gemma":[0.9994131,0.0000368591,0.0001030123,0.000203326,0.000136269,0.00004662092,0.000005100014,0.00001043341,0.00004528635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8920352,"threshold_uncertainty_score":0.2903277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07041064552524627,"score_gpt":0.3436837472503973,"score_spread":0.273273101725151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}